{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2015:PTAWQUQQU3J7U7ZFUWDY5ZOADW","short_pith_number":"pith:PTAWQUQQ","canonical_record":{"source":{"id":"1607.06720","kind":"arxiv","version":2},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2015-09-18T22:37:51Z","cross_cats_sorted":[],"title_canon_sha256":"4d9b1a327e892f8234e1a9b14b43f6f7ae4ea084da4b900b7e96c07429551a62","abstract_canon_sha256":"4909a16367b73c5074a41a59f33b927b41d223a63794328e797a0bfb20597a06"},"schema_version":"1.0"},"canonical_sha256":"7cc1685210a6d3fa7f25a5878ee5c01d95d9820b3eabcd6f76c27015e2efc610","source":{"kind":"arxiv","id":"1607.06720","version":2},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1607.06720","created_at":"2026-05-18T01:10:35Z"},{"alias_kind":"arxiv_version","alias_value":"1607.06720v2","created_at":"2026-05-18T01:10:35Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1607.06720","created_at":"2026-05-18T01:10:35Z"},{"alias_kind":"pith_short_12","alias_value":"PTAWQUQQU3J7","created_at":"2026-05-18T12:29:37Z"},{"alias_kind":"pith_short_16","alias_value":"PTAWQUQQU3J7U7ZF","created_at":"2026-05-18T12:29:37Z"},{"alias_kind":"pith_short_8","alias_value":"PTAWQUQQ","created_at":"2026-05-18T12:29:37Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2015:PTAWQUQQU3J7U7ZFUWDY5ZOADW","target":"record","payload":{"canonical_record":{"source":{"id":"1607.06720","kind":"arxiv","version":2},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2015-09-18T22:37:51Z","cross_cats_sorted":[],"title_canon_sha256":"4d9b1a327e892f8234e1a9b14b43f6f7ae4ea084da4b900b7e96c07429551a62","abstract_canon_sha256":"4909a16367b73c5074a41a59f33b927b41d223a63794328e797a0bfb20597a06"},"schema_version":"1.0"},"canonical_sha256":"7cc1685210a6d3fa7f25a5878ee5c01d95d9820b3eabcd6f76c27015e2efc610","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T01:10:35.691747Z","signature_b64":"LVIH+/yndvm71PwZBn0HNH2gKsegF2kWBnRZ6Bd6SyYRL7XWBDV+VkinHrXVvnOu/kh7bOqXiHD51D29/dqGDg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"7cc1685210a6d3fa7f25a5878ee5c01d95d9820b3eabcd6f76c27015e2efc610","last_reissued_at":"2026-05-18T01:10:35.691082Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T01:10:35.691082Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1607.06720","source_version":2,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T01:10:35Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"Rird+JimSlajuY3dsmPJYgrRNysTuqK7ufGh1doYcYXaJCvi4dg8jR4YU7rHoUrg6oWuSFlJYPLthbxfsZhuDA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-31T10:24:03.100728Z"},"content_sha256":"ab07c954d0cab141741730d266e13147bc62c6b2d6e138f589ea6e5d9fccc952","schema_version":"1.0","event_id":"sha256:ab07c954d0cab141741730d266e13147bc62c6b2d6e138f589ea6e5d9fccc952"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2015:PTAWQUQQU3J7U7ZFUWDY5ZOADW","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Perspective: Melanoma diagnosis and monitoring: Sunrise for melanoma therapy but early detection remains in the shade","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.TO","authors_text":"David Weaver, Pritiraj Mohanty, Remco Spanjaard, Shyamsunder Erramilli","submitted_at":"2015-09-18T22:37:51Z","abstract_excerpt":"Melanoma is one of the most dangerous forms of cancer. The five-year survival rate is 98% if it is detected early. However, this rate plummets to 63% for regional disease and 17% when tumors have metastasized, that is, spread to distant sites. Furthermore, the incidence of melanoma has been rising by about 3% per year, whereas the incidence of cancers that are more common is decreasing. A handful of targeted therapies have recently become available that have finally shown real promise for treatment, but for reasons that remain unclear only a fraction of patients respond long term. These drugs "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1607.06720","kind":"arxiv","version":2},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T01:10:35Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"Vf63Gi9EPJjknaePSkt2znTQMDDoGc44nbTVu/r6qE8+E5c8crXtyjSDx/D+0JZQ/J8BuECvbUAQaVx9zn1GDQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-31T10:24:03.101101Z"},"content_sha256":"b5e9b65715b64611dfea7203583392e4b3b84b2adcd892fbf16d4fa5a0c09bd8","schema_version":"1.0","event_id":"sha256:b5e9b65715b64611dfea7203583392e4b3b84b2adcd892fbf16d4fa5a0c09bd8"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/PTAWQUQQU3J7U7ZFUWDY5ZOADW/bundle.json","state_url":"https://pith.science/pith/PTAWQUQQU3J7U7ZFUWDY5ZOADW/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/PTAWQUQQU3J7U7ZFUWDY5ZOADW/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-05-31T10:24:03Z","links":{"resolver":"https://pith.science/pith/PTAWQUQQU3J7U7ZFUWDY5ZOADW","bundle":"https://pith.science/pith/PTAWQUQQU3J7U7ZFUWDY5ZOADW/bundle.json","state":"https://pith.science/pith/PTAWQUQQU3J7U7ZFUWDY5ZOADW/state.json","well_known_bundle":"https://pith.science/.well-known/pith/PTAWQUQQU3J7U7ZFUWDY5ZOADW/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2015:PTAWQUQQU3J7U7ZFUWDY5ZOADW","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"4909a16367b73c5074a41a59f33b927b41d223a63794328e797a0bfb20597a06","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2015-09-18T22:37:51Z","title_canon_sha256":"4d9b1a327e892f8234e1a9b14b43f6f7ae4ea084da4b900b7e96c07429551a62"},"schema_version":"1.0","source":{"id":"1607.06720","kind":"arxiv","version":2}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1607.06720","created_at":"2026-05-18T01:10:35Z"},{"alias_kind":"arxiv_version","alias_value":"1607.06720v2","created_at":"2026-05-18T01:10:35Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1607.06720","created_at":"2026-05-18T01:10:35Z"},{"alias_kind":"pith_short_12","alias_value":"PTAWQUQQU3J7","created_at":"2026-05-18T12:29:37Z"},{"alias_kind":"pith_short_16","alias_value":"PTAWQUQQU3J7U7ZF","created_at":"2026-05-18T12:29:37Z"},{"alias_kind":"pith_short_8","alias_value":"PTAWQUQQ","created_at":"2026-05-18T12:29:37Z"}],"graph_snapshots":[{"event_id":"sha256:b5e9b65715b64611dfea7203583392e4b3b84b2adcd892fbf16d4fa5a0c09bd8","target":"graph","created_at":"2026-05-18T01:10:35Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Melanoma is one of the most dangerous forms of cancer. The five-year survival rate is 98% if it is detected early. However, this rate plummets to 63% for regional disease and 17% when tumors have metastasized, that is, spread to distant sites. Furthermore, the incidence of melanoma has been rising by about 3% per year, whereas the incidence of cancers that are more common is decreasing. A handful of targeted therapies have recently become available that have finally shown real promise for treatment, but for reasons that remain unclear only a fraction of patients respond long term. These drugs ","authors_text":"David Weaver, Pritiraj Mohanty, Remco Spanjaard, Shyamsunder Erramilli","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2015-09-18T22:37:51Z","title":"Perspective: Melanoma diagnosis and monitoring: Sunrise for melanoma therapy but early detection remains in the shade"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1607.06720","kind":"arxiv","version":2},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:ab07c954d0cab141741730d266e13147bc62c6b2d6e138f589ea6e5d9fccc952","target":"record","created_at":"2026-05-18T01:10:35Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"4909a16367b73c5074a41a59f33b927b41d223a63794328e797a0bfb20597a06","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2015-09-18T22:37:51Z","title_canon_sha256":"4d9b1a327e892f8234e1a9b14b43f6f7ae4ea084da4b900b7e96c07429551a62"},"schema_version":"1.0","source":{"id":"1607.06720","kind":"arxiv","version":2}},"canonical_sha256":"7cc1685210a6d3fa7f25a5878ee5c01d95d9820b3eabcd6f76c27015e2efc610","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"7cc1685210a6d3fa7f25a5878ee5c01d95d9820b3eabcd6f76c27015e2efc610","first_computed_at":"2026-05-18T01:10:35.691082Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T01:10:35.691082Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"LVIH+/yndvm71PwZBn0HNH2gKsegF2kWBnRZ6Bd6SyYRL7XWBDV+VkinHrXVvnOu/kh7bOqXiHD51D29/dqGDg==","signature_status":"signed_v1","signed_at":"2026-05-18T01:10:35.691747Z","signed_message":"canonical_sha256_bytes"},"source_id":"1607.06720","source_kind":"arxiv","source_version":2}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:ab07c954d0cab141741730d266e13147bc62c6b2d6e138f589ea6e5d9fccc952","sha256:b5e9b65715b64611dfea7203583392e4b3b84b2adcd892fbf16d4fa5a0c09bd8"],"state_sha256":"5c184432304c2c6e981e1556ad8b2f0ab6ea515d0688f18f694c00042704590f"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"RUxFa9r72mVY5oMDpiNDLsHdmiM3/W638gamuqEdGhczWBk4nMN3IqgpTUEFebrtmeqgiTEsw7j1LosjJss5DQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-05-31T10:24:03.104380Z","bundle_sha256":"8beff7183d1f8d87b486ca2979533a013bcd0ecd877718f65b10c4f46e24b9cc"}}